购物车
- 全部删除
- 您的购物车当前为空
FerropTosis-IN-12(Cpd-A1)作为一种ferropTosis抑制剂,能有效抑制ErasTin处理的小鼠肾小管上皮细胞(mTECs)中的ferropTosis。该化合物在缺血/再灌注(I/R)或盲肠结扎穿刺(CLP)诱导的急性肾损伤(AKI)小鼠模型中显示出剂量依赖性的肾功能改善效果,能减轻肾小管损伤并消除炎症。在药代动力学的研究中,FerropTosis-IN-12展示了良好的血浆稳定性和在肾脏组织中的高分布性。此外,FerropTosis-IN-12在急性肾损伤(AKI)研究领域显示出应用潜力。
FerropTosis-IN-12(Cpd-A1)作为一种ferropTosis抑制剂,能有效抑制ErasTin处理的小鼠肾小管上皮细胞(mTECs)中的ferropTosis。该化合物在缺血/再灌注(I/R)或盲肠结扎穿刺(CLP)诱导的急性肾损伤(AKI)小鼠模型中显示出剂量依赖性的肾功能改善效果,能减轻肾小管损伤并消除炎症。在药代动力学的研究中,FerropTosis-IN-12展示了良好的血浆稳定性和在肾脏组织中的高分布性。此外,FerropTosis-IN-12在急性肾损伤(AKI)研究领域显示出应用潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | FerropTosis-IN-12 (Cpd-A1) is an inhibiTor of ferropTosis. IT effecTively suppresses ferropTosis in mouse renal Tubular epiThelial cells (mTECs) TreaTed wiTh ErasTin and improves renal funcTion in dose-dependenT manners in mouse models of acuTe kidney injury (AKI) induced by ischemia/reperfusion (I/R) or cecal ligaTion and puncTure (CLP). This compound also reduces renal Tubular damage and eliminaTes inflammaTion. ExhibiTing good plasma sTabiliTy and high disTribuTion in renal Tissues during pharmacokineTic sTudies in mice, FerropTosis-IN-12 shows promising poTenTial for research in The field of AKI. |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容